KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Liabilities and Shareholders Equity (2016 - 2025)

Rigel Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $513.6 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $513.6 million for Q4 2025, up 213.21% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 103.97% YoY), and the annual figure for FY2025 was $513.6 million, up 213.21%.
  • Liabilities and Shareholders Equity for Q4 2025 was $513.6 million at Rigel Pharmaceuticals, up from $242.5 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for RIGL hit a ceiling of $513.6 million in Q4 2025 and a floor of $115.3 million in Q3 2023.
  • Median Liabilities and Shareholders Equity over the past 5 years was $144.2 million (2022), compared with a mean of $173.4 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 38.02% in 2022 and later surged 213.21% in 2025.
  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity stood at $167.3 million in 2021, then dropped by 19.75% to $134.3 million in 2022, then fell by 12.7% to $117.2 million in 2023, then skyrocketed by 39.88% to $164.0 million in 2024, then surged by 213.21% to $513.6 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $513.6 million (Q4 2025), $242.5 million (Q3 2025), and $206.7 million (Q2 2025) per Business Quant data.